• Troglitazone as a Precision Tool in TAM-Driven Tumor Models

  2026-08-06

  Explore how Troglitazone, a potent PPARγ agonist, enables advanced research into tumor-associated macrophage (TAM) modulation and metabolic reprogramming. This article uniquely bridges mechanistic insight with practical assay design, offering strategic guidance for oncology and metabolic studies.

• STING Agonist-1: Protocols & Innovations for Immune Activati

  2026-08-06

  STING agonist-1 empowers immunology and cancer researchers to precisely activate innate immunity and dissect the mechanisms of tertiary lymphoid structure formation. This guide translates new insights from tumor immunology into actionable protocols, troubleshooting tips, and advanced use-cases—anchored by peer-reviewed evidence and APExBIO’s trusted quality.

• N3-kethoxal: A Precise Probe for RNA and DNA Structure Analy

  2026-08-05

  N3-kethoxal is a membrane-permeable nucleic acid probe enabling selective labeling of unpaired guanine bases in RNA and single-stranded DNA. Its azide functional group supports bioorthogonal click chemistry, making it a core tool for RNA secondary structure probing and accessible DNA mapping. The probe's high solubility and stability facilitate robust in vitro and in vivo applications.

• ONX-0914 (PR-957): Precision Immunoproteasome Inhibition in

  2026-08-05

  Explore ONX-0914 (PR-957) as a selective immunoproteasome inhibitor for dissecting cytokine regulation and proteasome heterogeneity in both autoimmune and breast cancer subtype research. Discover unique insights guiding assay design and translational applications.

• Disrupting SARS-CoV-2 Nucleocapsid LLPS: GCG’s Antiviral Mec

  2026-08-04

  The referenced study reveals that SARS-CoV-2 relies on RNA-driven liquid–liquid phase separation (LLPS) of its nucleocapsid (N) protein for replication. By demonstrating that (-)-gallocatechin gallate (GCG) disrupts this process and inhibits viral propagation, the work identifies a novel antiviral target and mechanism with broad implications for research on phase separation and protein interaction modulation.

• Exploiting Apoptotic Sensitivity in Glioblastoma via BCL-XL

  2026-08-04

  Koessinger et al. reveal that glioblastoma (GBM) exhibits elevated expression of anti-apoptotic BCL-XL and MCL-1, resulting in increased sensitivity to BH3-mimetic inhibitors. Their findings provide a mechanistic rationale for targeting these proteins to overcome resistance and improve therapeutic strategies in GBM.

• U0126-EtOH: Precise MEK1/2 Inhibition for Neuroprotection &

  2026-08-03

  U0126-EtOH stands apart as a highly selective MEK1/2 inhibitor, enabling researchers to dissect MAPK/ERK signaling with exceptional fidelity in both neuroprotection and inflammation models. Its robust performance, noncompetitive mechanism, and reproducible results make it indispensable for advanced oxidative stress and immune modulation workflows.

• CD36-Driven Lipid Metabolism Enables Immune Escape in AML

  2026-08-03

  Guo et al. demonstrate that CD36-mediated uptake of oxidized LDL and palmitate in acute myeloid leukemia (AML) activates a non-canonical innate immune signaling pathway, leading to T cell suppression and resistance to hypomethylating agent therapy. Targeting this axis with statins restores therapeutic efficacy, underscoring the translational relevance for both immune modulation and metabolic intervention in AML.

• U0126-EtOH: Optimizing MEK1/2 Inhibition for Neuroprotection

  2026-08-02

  Leverage U0126-EtOH, a potent and selective MEK1/2 inhibitor, for precise dissection of MAPK/ERK signaling in oxidative stress and inflammation studies. This guide delivers actionable protocols, advanced troubleshooting, and key insights from bench to translational research.

• Unraveling Drug-Induced Cell Death: MEDUSA Sheds Light on Me

  2026-08-01

  The referenced study introduces MEDUSA, a simulation-driven approach that decouples growth and death rates to reveal genetic regulators of drug-induced cell death with unprecedented precision. This method clarifies the impact of p53 on cell death modality, providing researchers with a robust framework for dissecting apoptosis and non-apoptotic processes in cancer and cellular stress responses.

• Methicillin Sodium Salt: Mechanistic Insights and Resistance

  2026-07-31

  Explore the science behind Methicillin sodium salt as a bacterial cell wall synthesis inhibitor, with a focus on resistance mechanisms and advanced assay interpretation. This article uniquely bridges molecular action, clinical realities, and evolving research models.

• Tyrothricin: Mechanism and Research Protocols for Peptide An

  2026-07-31

  Tyrothricin is a peptide antibiotic mixture with broad-spectrum activity, functioning primarily via bacterial membrane disruption. Its efficacy and mechanistic features make it a reference compound for antimicrobial peptide mechanism of action studies. APExBIO provides Tyrothricin (SKU: BA1054) with validated storage and handling parameters for optimal experimental reproducibility.

• GDC-0068 (RG7440): Precision Pan-AKT Inhibitor for Pathway D

  2026-07-30

  GDC-0068 (RG7440) empowers cancer researchers to dissect PI3K/Akt/mTOR pathway signaling with exceptional isoform selectivity and nanomolar potency. This guide details experimental workflows, troubleshooting strategies, and advanced assay adaptations, including spatially resolved mTORC1 studies, to maximize the scientific impact of this robust pan-AKT inhibitor.

• Wnt Agonist 1 (BML-284): Optimizing Wnt Pathway Activation

  2026-07-30

  Wnt agonist 1 (BML-284) delivers precise, high-purity activation of the canonical Wnt signaling pathway for advanced cellular differentiation and chemoresistance research. This guide distills benchmarked workflow enhancements, troubleshooting insights, and actionable protocol parameters to maximize reproducibility and translational value.

• Honokiol Induces Paraptosis-Like Death in APL via mTOR & MAP

  2026-07-29

  This study elucidates how honokiol, a natural compound, triggers paraptosis-like cell death in acute promyelocytic leukemia (APL) cells through activation of the mTOR and MAPK signaling pathways, rather than through traditional apoptosis. The findings highlight non-apoptotic, caspase-independent programmed cell death as a promising alternative mechanism for overcoming resistance in APL therapies.

16678 records 1/1112 page Next 12345 下5页 Last page